Communiqués Neurocrine Biosciences, Inc.

Actions

NBIX

US64125C1099

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
143,47 ^USD	-1,40%		+1,15%	+1,16%

19:44	Un groupe pharmaceutique poursuit le gouvernement américain au sujet de la réglementation sur le prix des médicaments de Medicare	MT
30/09	Neurocrine Biosciences, Inc. annonce de nouvelles recherches permettant de mieux comprendre le syndrome de Prader-Willi et d’élargir les données cliniques et en vie réelle sur Vykat XR	CI

Communiqués

01/10	Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT XR at Foundation for Prader-Willi Research Symposium and Family Conference	AQ
30/09	Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference	PR
28/09	Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer	PR
02/09	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September	PR
12/08	Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia	PR
10/08	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist	AQ
07/08	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist	PR
30/07	Neurocrine: Q2 Earnings Snapshot	AQ
30/07	Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results	PR
23/07	Neurocrine Biosciences Announces Key Leadership Hiring, Promotions	PR
21/07	Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer	PR
09/07	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results	PR
01/07	Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia	PR
16/06	Neurocrine Biosciences Presents New Two-Year CRENESSITY Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026	AQ
15/06	Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period	PR
15/06	Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026	PR
15/06	Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026	PR
15/06	Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026	PR
08/06	Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients	PR
08/06	Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities	PR
03/06	Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026	PR
26/05	Neurocrine Biosciences to Present at Upcoming Investor Conferences in June	PR
18/05	Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules	PR
18/05	Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics	PR
06/05	Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia	PR